BLACK DIAMOND THERAPEUTICS I
BDTXNASDAQTrading Snapshot
- Day Range
- $1.85 – $1.90
- 52-Week Range
- $1.60 – $4.94
- Volume
- $2.63B
- Avg Volume
- $3.10B
- Shares Outstanding
- 57.3M
- Next Earnings
- Nov 10, 2026
Fundamentals Snapshot
- Annual Revenue
- $70M
- Last Q Revenue
- $18M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.74
- Dividend Yield
- —
- Dilution (1yr)
- +0.9%
Why Investors Own BDTX
- ✓High-growth profile — revenue up +38.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 48% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BLACK DIAMOND THERAPEUTICS I
BDTX
StockOtter · stockotter.spaceAbout BLACK DIAMOND THERAPEUTICS I
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Reviewing Pliant Therapeutics (NASDAQ:PLRX) & Black Diamond Therapeutics (NASDAQ:BDTX)
Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) and Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two compan
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patien
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patient
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX's lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR, targeting